The following is a summary of “Tacrolimus as first line therapy in a U.S. cohort of idiopathic inflammatory myopathies ...

Participants with higher forced vital capacity, indicating better lung function, were less likely to develop heart disease, diabetes, and stroke over 10 years.

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the company to seek approval for the asset in a second condition. Topline data from ...

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...

Around 20% to 25% of individuals with rapidly declining FEV 1 /FVC trajectories experienced wheezing and usual phlegm/bronchitis as adolescents/young adults, according to results published in The ...

Jacobs put a huge scare into Crystal Lake South’s potential Fox Valley Conference title hopes during their matchup Tuesday night. The Golden Eagles led for much of the second quarter and the entire ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

“The atmosphere was awesome,” Maness said after the Warriors improved to 20-2 and 12-0 in the FVC, two games ahead of second-place South (20-4, 10-2). Each team has six conference games lef ...